Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535999 · ClinicalTrials.gov registry record · Phase 4
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT04535999: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT04535999 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04535999, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.
Interventions
- DRUG Secukinumab Auto-Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04535999
The ClinicalTrials.gov registry entry for NCT04535999 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab Auto-Injector is the first listed.
NCT04535999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04535999 about?
NCT04535999 is a clinical study titled "Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)". This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.
What is the current status of trial NCT04535999?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2022-02-07. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT04535999?
The interventions under investigation include: Secukinumab Auto-Injector (DRUG).
Who is sponsoring clinical trial NCT04535999?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.